Main Clinical, Molecular, Transcriptomic, and Methylation Features in Responder Versus Nonresponder Patients.
| Variable . | Responders (n = 3) . | Non-responders (n = 9) . |
|---|---|---|
| Clinical | ||
| Age at inclusion (years), median (range) | 67 (46–71) | 61 (36–87) |
| Number of prior relapses | ||
| 1 | 3 (100 %) | 5 (56%) |
| >1 | 0 | 4 (44%) |
| ECOG performance status | ||
| 0–1 | 2 (67%) | 6 (67%) |
| 2 | 1 (33%) | 3 (33%) |
| Glucocorticoids use | ||
| Yes | 3 (100%) | 6 (67%) |
| No | 0 (0%) | 3 (33%) |
| Histological | ||
| 2016 WHO classification, n (%) | ||
| Grade III astrocytoma, IDH wildtype | 1 (33%) | 1 (11%) |
| Grade IV glioblastoma, IDH wildtype | 2 (67%) | 8 (89%) |
| Molecular | ||
| MGMT | ||
| Methylated | 1 (33%) | 1 (13%) |
| Unmethylated | 2 (67 %) | 7 (87%) |
| NA | 0 | 1 |
| MDM2 | ||
| Amplified | 0 (0%) | 1 (20%) |
| Normal | 2 (100%) | 5 (80%) |
| NA | 1 | 3 |
| CDK4 | ||
| Amplified | 0 (0%) | 0 (0%) |
| Normal | 2 (100%) | 6 (100%) |
| NA | 1 | 3 |
| Transcriptomic | ||
| Verhaak classification | ||
| Classical | 1 (33%) | 3 (60%) |
| Mesenchymal | 0 | 2 (40%) |
| Proneural | 2 (67%) | 0 |
| NA | 0 | 4 |
| Iavarone classification | ||
| Mitochondrial | 1 (33%) | 3 (60%) |
| Glycolytic/plurimetabolic | 0 | 1 (20%) |
| Proliferative/progenitor | 0 | 1 (20%) |
| Neuronal | 2 (67%) | 0 |
| NA | 0 | 4 |
| Methylation | ||
| DKFZ methylation class, v11b4 | ||
| Glioblastoma, IDH wildtype | 3 (100%) | 5 (83%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| DKFZ methylation family, v11b4 | ||
| Glioblastoma, mesenchymal | 3 (100%) | 2 (33%) |
| Glioblastoma, RTK II | 0 | 3 (50%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| Variable . | Responders (n = 3) . | Non-responders (n = 9) . |
|---|---|---|
| Clinical | ||
| Age at inclusion (years), median (range) | 67 (46–71) | 61 (36–87) |
| Number of prior relapses | ||
| 1 | 3 (100 %) | 5 (56%) |
| >1 | 0 | 4 (44%) |
| ECOG performance status | ||
| 0–1 | 2 (67%) | 6 (67%) |
| 2 | 1 (33%) | 3 (33%) |
| Glucocorticoids use | ||
| Yes | 3 (100%) | 6 (67%) |
| No | 0 (0%) | 3 (33%) |
| Histological | ||
| 2016 WHO classification, n (%) | ||
| Grade III astrocytoma, IDH wildtype | 1 (33%) | 1 (11%) |
| Grade IV glioblastoma, IDH wildtype | 2 (67%) | 8 (89%) |
| Molecular | ||
| MGMT | ||
| Methylated | 1 (33%) | 1 (13%) |
| Unmethylated | 2 (67 %) | 7 (87%) |
| NA | 0 | 1 |
| MDM2 | ||
| Amplified | 0 (0%) | 1 (20%) |
| Normal | 2 (100%) | 5 (80%) |
| NA | 1 | 3 |
| CDK4 | ||
| Amplified | 0 (0%) | 0 (0%) |
| Normal | 2 (100%) | 6 (100%) |
| NA | 1 | 3 |
| Transcriptomic | ||
| Verhaak classification | ||
| Classical | 1 (33%) | 3 (60%) |
| Mesenchymal | 0 | 2 (40%) |
| Proneural | 2 (67%) | 0 |
| NA | 0 | 4 |
| Iavarone classification | ||
| Mitochondrial | 1 (33%) | 3 (60%) |
| Glycolytic/plurimetabolic | 0 | 1 (20%) |
| Proliferative/progenitor | 0 | 1 (20%) |
| Neuronal | 2 (67%) | 0 |
| NA | 0 | 4 |
| Methylation | ||
| DKFZ methylation class, v11b4 | ||
| Glioblastoma, IDH wildtype | 3 (100%) | 5 (83%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| DKFZ methylation family, v11b4 | ||
| Glioblastoma, mesenchymal | 3 (100%) | 2 (33%) |
| Glioblastoma, RTK II | 0 | 3 (50%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
NA = not available.
Main Clinical, Molecular, Transcriptomic, and Methylation Features in Responder Versus Nonresponder Patients.
| Variable . | Responders (n = 3) . | Non-responders (n = 9) . |
|---|---|---|
| Clinical | ||
| Age at inclusion (years), median (range) | 67 (46–71) | 61 (36–87) |
| Number of prior relapses | ||
| 1 | 3 (100 %) | 5 (56%) |
| >1 | 0 | 4 (44%) |
| ECOG performance status | ||
| 0–1 | 2 (67%) | 6 (67%) |
| 2 | 1 (33%) | 3 (33%) |
| Glucocorticoids use | ||
| Yes | 3 (100%) | 6 (67%) |
| No | 0 (0%) | 3 (33%) |
| Histological | ||
| 2016 WHO classification, n (%) | ||
| Grade III astrocytoma, IDH wildtype | 1 (33%) | 1 (11%) |
| Grade IV glioblastoma, IDH wildtype | 2 (67%) | 8 (89%) |
| Molecular | ||
| MGMT | ||
| Methylated | 1 (33%) | 1 (13%) |
| Unmethylated | 2 (67 %) | 7 (87%) |
| NA | 0 | 1 |
| MDM2 | ||
| Amplified | 0 (0%) | 1 (20%) |
| Normal | 2 (100%) | 5 (80%) |
| NA | 1 | 3 |
| CDK4 | ||
| Amplified | 0 (0%) | 0 (0%) |
| Normal | 2 (100%) | 6 (100%) |
| NA | 1 | 3 |
| Transcriptomic | ||
| Verhaak classification | ||
| Classical | 1 (33%) | 3 (60%) |
| Mesenchymal | 0 | 2 (40%) |
| Proneural | 2 (67%) | 0 |
| NA | 0 | 4 |
| Iavarone classification | ||
| Mitochondrial | 1 (33%) | 3 (60%) |
| Glycolytic/plurimetabolic | 0 | 1 (20%) |
| Proliferative/progenitor | 0 | 1 (20%) |
| Neuronal | 2 (67%) | 0 |
| NA | 0 | 4 |
| Methylation | ||
| DKFZ methylation class, v11b4 | ||
| Glioblastoma, IDH wildtype | 3 (100%) | 5 (83%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| DKFZ methylation family, v11b4 | ||
| Glioblastoma, mesenchymal | 3 (100%) | 2 (33%) |
| Glioblastoma, RTK II | 0 | 3 (50%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| Variable . | Responders (n = 3) . | Non-responders (n = 9) . |
|---|---|---|
| Clinical | ||
| Age at inclusion (years), median (range) | 67 (46–71) | 61 (36–87) |
| Number of prior relapses | ||
| 1 | 3 (100 %) | 5 (56%) |
| >1 | 0 | 4 (44%) |
| ECOG performance status | ||
| 0–1 | 2 (67%) | 6 (67%) |
| 2 | 1 (33%) | 3 (33%) |
| Glucocorticoids use | ||
| Yes | 3 (100%) | 6 (67%) |
| No | 0 (0%) | 3 (33%) |
| Histological | ||
| 2016 WHO classification, n (%) | ||
| Grade III astrocytoma, IDH wildtype | 1 (33%) | 1 (11%) |
| Grade IV glioblastoma, IDH wildtype | 2 (67%) | 8 (89%) |
| Molecular | ||
| MGMT | ||
| Methylated | 1 (33%) | 1 (13%) |
| Unmethylated | 2 (67 %) | 7 (87%) |
| NA | 0 | 1 |
| MDM2 | ||
| Amplified | 0 (0%) | 1 (20%) |
| Normal | 2 (100%) | 5 (80%) |
| NA | 1 | 3 |
| CDK4 | ||
| Amplified | 0 (0%) | 0 (0%) |
| Normal | 2 (100%) | 6 (100%) |
| NA | 1 | 3 |
| Transcriptomic | ||
| Verhaak classification | ||
| Classical | 1 (33%) | 3 (60%) |
| Mesenchymal | 0 | 2 (40%) |
| Proneural | 2 (67%) | 0 |
| NA | 0 | 4 |
| Iavarone classification | ||
| Mitochondrial | 1 (33%) | 3 (60%) |
| Glycolytic/plurimetabolic | 0 | 1 (20%) |
| Proliferative/progenitor | 0 | 1 (20%) |
| Neuronal | 2 (67%) | 0 |
| NA | 0 | 4 |
| Methylation | ||
| DKFZ methylation class, v11b4 | ||
| Glioblastoma, IDH wildtype | 3 (100%) | 5 (83%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
| DKFZ methylation family, v11b4 | ||
| Glioblastoma, mesenchymal | 3 (100%) | 2 (33%) |
| Glioblastoma, RTK II | 0 | 3 (50%) |
| No match | 0 | 1 (17%) |
| NA | 0 | 3 |
NA = not available.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
